Anbio Biotechnology Shareholder Meeting and Capital Changes

Anbio Biotechnology is holding an extraordinary general meeting of shareholders on May 15, 2026. The meeting will address several key proposals, including a reduction of the company's authorized share capital, an increase in authorized share capital with the creation of new share classes (Class C Ordinary Shares and Preference Shares), an increase in the voting rights of Class B Ordinary Shares from 50 to 500 votes per share, and the conversion of Class B Ordinary Shares into Class A Ordinary Shares. Shareholders will also vote on authorizing the board to implement share consolidations for Class A Ordinary Shares, with ratios ranging from 2-for-1 to 10,000-for-1, to meet Nasdaq's minimum bid price requirement and avoid delisting. Additionally, the company proposes to adopt a restated memorandum and articles of association to reflect these changes and other administrative updates. The board unanimously recommends voting "FOR" all proposals.